Table 1 Patients’ characteristics
Characteristic | N (%) |
|---|---|
Sex | |
 Male | 154 (77%) |
 Female | 47 (23%) |
 Age | 61 (55-68) |
Tumor site | |
 Oropharynx | 84 (42%) |
 Oral Cavity | 45 (22%) |
 Larynx | 26 (13%) |
 Other | 46 (23%) |
P-16 status | |
 Negative | 132 (66%) |
 Positive | 69 (34%) |
IO line of therapy | |
 1 | 98 (49%) |
 2 and beyond | 103 (51%) |
Immunotherapy drug | |
 Pembrolizumab | 100 (50%) |
 Nivolumab | 91 (45%) |
 Nivolumab + Ipilimumab | 10 (5.0%) |
ECOG | |
 0 | 36 (18%) |
 1 | 96 (48%) |
 2 and 3 | 69 (34%) |